BMJ  2007;334:54-55 (13 January), doi:10.1136/bmj.39050.576644.80

Editorials

Chronic hepatitis C

Antiviral therapy is approved by NICE but too few patients receive it

The first 150 words of the full text of this article appear below.

Hepatitis C infection is a treatable disease.1 Generally, people with chronic hepatitis C are relatively asymptomatic but risk progression over time to cirrhosis and its complications. Combination antiviral therapy with pegylated interferon and ribavirin achieves sustained virological response rates of 42-80% depending on genotype.2 In August 2006 the National Institute for Health and Clinical Excellence (NICE) published updated guidelines for the management of patients with this infection.3 The guidance allows antiviral therapy for patients with hepatitis C viral RNA without the need for liver biopsy. This is a major change to the traditional practice of restricting treatment to patients with moderate or severe disease on liver biopsy.

Specialists in the field, who are keen to increase the uptake of treatment in eligible patients, will welcome the new guidance. However, they together with people infected with the virus and those who seek to deliver appropriate medical care will remain frustrated. Although . . . [Full text of this article]

Kosh Agarwal, consultant hepatologist 1, Timothy J S Cross, research fellow1, Charles Gore, chief executive2

1 Institute of Liver Studies, King's College Hospital, London SE5 9RS, 2 Hepatitis C Trust, London SE1 3YD

kosh.agarwal@kch.nhs.uk


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Diagnosis and treatment of chronic hepatitis C infection
Keyur Patel, Andrew J Muir, and John G McHutchison
BMJ 2006 332: 1013-1017. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Cross, T J S, Antoniades, C G, Harrison, P M (2008). Current and future management of chronic hepatitis C infection. Postgrad. Med. J. 84: 172-176 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

Pharmacoeconomics: adding an “adjunctive” comparison contrasting innovative treatment vs no treatment in cases where the original clinical trial compared innovative treatment vs reference treatment
Andrea Messori
bmj.com, 19 Aug 2008 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ